English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Aims The aim of this study is to evaluate health-related outcomes in patients aged 70 years and above diagnosed with glioblastoma multiforme (GBM) in NHS Tayside between 2017-2020. Objectives include identification of factors which influence the oncological treatment modalities pursued; disease progression/recurrence and outcomes within each treatment modality category. Method Medical databases were reviewed retrospectively to identify patients aged 70 years and above diagnosed with GBM in NHS Tayside, between 2017-2020. Analysed data identified patients' past medical history, symptoms and investigations preceding diagnosis; date of first brain imaging which demonstrated abnormality in-keeping with a likely diagnosis of GBM; factors influencing treatment modalities undertaken, molecular and genetic analysis of tumour samples; disease recurrence/progression, and date of death if applicable. Results 54 patients diagnosed with GBM. 13 patients were aged over 70 years. 8 males, 5 females. Commonest co-morbid conditions were hypertension and gout. 2/13 received best supportive care only, based on poor performance status and extensive disease burden. 9/13 underwent neurosurgery; 7 debulked; 2 biopsy only. 7 isocitrate dehydrogenase (IDH1) wild-type; 2 IDH classification not known. 3 MGMT methylated; 4 unmethylated; 2 MGMT classification not known.3/13 received temozolomide (TMZ) alone. 2 later received palliative radiotherapy (30Gy in 6 #) to control symptoms. 4/13 received 40Gy in 15 # with concurrent TMZ 4/13 received 60Gy in 30 # with concurrent TMZ. 5 received adjuvant TMZ following initial chemo-radiation: 3 after 40Gy and 2 after 60Gy. As of March 2021, 6/13 were alive, including all 4 who had received hypofractionated radiotherapy. 4 of these continue to demonstrate stable disease on most recent imaging. Conclusion Baseline fitness levels of patients were generally high, with few having significant co-morbidity pre-diagnosis. Prognosis and morbidity was significantly poorer in patients who did not undergo any form of radiotherapy. Patients who received hypofractionated radiotherapy demonstrated most favourable health-related outcomes, demonstrating longest survival and least evidence of disease recurrence/progression.Although the sample size for this study is small, it highlights the potential benefits of radiotherapy on survival, particularly hypofractionated courses such as 40Gy in 15 fractions in a real-world population, even during a global pandemic. It would be useful to prospectively follow-up elderly patients with GBM to assess outcomes and quality of life.

Evaluation of health outcomes in patients aged 70 years and above with glioblastoma multiforme in NHS Tayside between 2017-2020